GI Dynamics, Inc. designs, develops, and markets medical devices for non-surgical approaches to treating type 2 diabetes and obesity. The Company has commercially launched its lead product, the EndoBarrier. EndoBarrier Therapy is a treatment for people whose diabetes medications are no longer effective, who are at risk for serious health complications from their diabetes and excess weight and who want to avoid surgery or the progression to injectable therapy. The Company’s product is sold to customers located in Europe, the Middle East, Australia and South America. The Company is focused on the commercial rollout of the EndoBarrier in selected countries in Europe and South America, as well as in Australia and Israel. In the United States, it has received approval from the United States Food and Drug Administration (FDA), to commence its clinical trial, which began in 2013.